Capmatinib, the world’s first new MET-targeting drug: mechanism analysis, medication guide and Chinese and foreign prices revealed

As the first targeted drug for MET exon 14 skip mutation NSCLC to receive routine approval from the FDA, capmatinib not only expands the anti-tumor front, but also becomes the focus of the times due to domestic medical insurance inclusion and imitation impact.

What is capmatinib? The innovative significance of precise targeting

Capmatinib (Capmatinib, trade name Tabrecta) is the first highly selective MET receptor tyrosine kinase inhibitor jointly developed by Incyte and Novartis, specifically targeting MET exon14 skipping mutation NSCLC (non-small cell lung cancer). This mutation is found in approximately 3–4% of NSCLC patients, providing a revolutionary direction and possibility for precision tumor treatment. Capmatinib received accelerated approval from the FDA in May 2020, and has been successively launched in the United States, Europe, Japan, and China, and will be included in China's medical insurance directory in 2024.

Target mechanism revealed: BreakingMET jump mutation cancer-killing chain

MET exon14 skipping mutations result in loss of the receptor regulatory region, thereby escaping degradation and inducing sustained activation of oncogenic signaling. Capmatinib binds to the c-MET ATP site with high selectivity, effectively blocks receptor phosphorylation, inhibits the downstream PI3K/AKT and MAPK signaling pathways, and ultimately cuts off tumor proliferation, survival and metastasis pathways. MET exon14 skipping mutations prevent the receptor from being degraded and the signal continues to be abnormally amplified. Capmatinib is designed to effectively intervene in this mechanism. This mechanism makes it outstandingly effective but low in inhibitory effects on non-MET-driven cells, so the toxicity is relatively controllable and better tolerated. Compared with traditional treatment methods, achieving precise therapeutic effects is one of the important directions for future cancer treatment.

Clinical trial data:GEOMETRY mono-1 demonstrates efficacy

Trial Overview:GEOMETRY mono1 (NCT02414139), a multi-center phase II open study, enrolling patients with MET exon14 skip mutation NSCLC

Treatment regimen: Standard adult dose is 400 mg twice daily, administered orally until disease progression or intolerable toxicity.

Efficacy Highlights:

Treatment-naïve patients ORR reached 68%, median DOR was 16.6 months;

Previously treated patients ORR ~41%, median DOR ~9.7 months.

Security Overview:

Common adverse reactions include peripheral edema (>50%), nausea, fatigue, etc.;

Serious adverse events such as interstitial lung disease and liver toxicity may occur and require close observation

European Approval Basis:GEOMETRY data supports EU approval of Tabrecta in 2022 for this precise population

Guidelines for Dosage and Tolerance Management

Standard usage: twice daily, each time400 mg, taken orally, no fixed meals required

Tolerability strategy: For the first time≥Grade 3 reaction, reduce the dose to 300mg BID; for another reaction, continue to reduce the dose to 200mg BID; if it is intolerable, consider discontinuing the drug.

Key monitoring indicators: liver function, pulmonary symptoms, skin photosensitivity, pancreatic enzymes, etc. It is not recommended to use it in combination with strong CYP3A inducers; contraception should be used during pregnancy

Comparison of Chinese and foreign prices: extreme differences between medical insurance assistance and market price differences

Domestic original research capmatinib—an affordable solution supported by medical insurance

Specifications and price:200mg×60 tablets or 150mg×60 tablets, each box is about RMB RMB 30,000.

Medical insurance policy: It is included in the national medical insurance catalog, and the reimbursement ratio is based on local policies. The actual patient out-of-pocket price is significantly lower than the market quotation.

The original research price in the Hong Kong market, the retail price of 200 mg × 60 tablets is more than 20,000 yuan;

Original research price in the European market——High costs under the influence of exchange rates and policies

According to EMA data, the retail price of 60 tablets of 200mg capmatinib is as high as more than 50,000 yuan;

Overseas generic drug market——The price is low but the quality needs to be screened

Generic drugs produced in Laos:

For example, the ex-factory price of Lucius(200mg×60) in Laos is about more than 2,000 yuan in RMB discount;

xa0

Drug selection strategy: balancing efficacy, safety and cost

Advantages of original research: reliable quality, safe efficacy and rigorous clinical verification; medical insurance support, compliance and use, suitable for patients with routine treatment.

Advantages of imitation: low price, benefiting those with limited ability to pay; however, quality and approval compliance must be ensured.

Clinical recommendations: Patients with medical insurance prefer original research; those without medical insurance or budget constraints can consult regular channels for generic products; doctors need to monitor efficacy, side effects and drug interactions.

Future Outlook: Trends in Indications Expansion and Dose Optimization

Potential for dose adjustment: Real-world data show that reduction to 300/200mg BID does not affect efficacy but improves tolerability.

Indications expansion:MET amplified NSCLC, combined immune/anti-vascular therapy, liver cancer and other directions are being actively promoted in multi-center phase II/III trials.

Data accumulation in China: With the large-scale use of medical insurance, a wealth of real-world evidence will be formed to assist the formulation of local standards and economic research on efficacy.

Summary:The pioneering era of Met targeting has arrived, and capmatinib is gradually gaining popularity

Capmatinib has become the backbone of MET exon14 NSCLC treatment field with its precise mechanism, remarkable efficacy and medical insurance support.MET exon14 Faced with the high prices of original drugs and the impact of generic drugs, patients are eager to balance quality and economy. In the future, attention will be paid to dose optimization, combination therapy expansion and Chinese local data, which will help form better treatment paths.

xa0

References:

https://www.drugs.com/mtm/capmatinib.html

https://go.drugbank.com/drugs/DB11791

https://www.onclive.com/view/capmatinib-approved-in-europe-for-metex14-altered-advanced-nsclc?utm_source=chatgpt.com

https://ingpharma.com/?s=/goods/lists.html&keyword=Capmatinib